Table S1. Phenotype of immune cell subsets. An overview of the used phenotypic definitions for each of the assessed immune subsets and analyzed activation/checkpoint molecules (PDF 510 kb
Figure S1. Expression of CD19/CD20, CD79A/B and RAG1/RAG2 in blood cancer cell lines. X axis: 164 bl...
quanTIseq signature matrix and used RNA-seq data from purified/enriched immune cells. RNA-seq data: ...
Table S1. Number of patients for breast cancer subtype in the TCGA dataset according to IHC status. ...
Figure S2. Frequency and activation state of DC subsets in HLN compared to metastasis negative (SLN-...
Figure S1. Flowcytometric gating of cell subsets. Gating strategies for the DC subsets as well as Tr...
Figure S5. Frequencies and expression of surface molecules of DC subsets in relation to BrC subtype ...
Figure S4. TLR7 and TLR8 expression in LN DC subsets and R848-induced activation in tumor negative B...
Figure S3. Prognostic effect of LNRcDC CD86 expression levels. Kaplan Meier curves of estimated DFS ...
Patient and Tumour Characteristics, Responses to Neoadjuvant Chemotherapy (nâ=â33). (DOCX 56Â kb
Table S5. Differentially expressed genes representing specific immune cell populations across all th...
Figure S2. Phenotypic analyses of breast duct lymphocytes. a CD161, IL-18Rα, and PLZF expression on ...
Figure S1. Representative staining of ILC populations. ILC were gated on lineage negative, CD45+, CD...
Figure S1. Representative immunohistochemistry (IHC) staining images for CD8, CD4, CD20 and CD68. Im...
Figure S1. Isolation and phenotypic analysis of cDC1s from the spleen of FLT3L-expressing B16 tumor-...
Patient characteristics. Table S2. Antibodies and immunostaining protocols. Table S3. Associations b...
Figure S1. Expression of CD19/CD20, CD79A/B and RAG1/RAG2 in blood cancer cell lines. X axis: 164 bl...
quanTIseq signature matrix and used RNA-seq data from purified/enriched immune cells. RNA-seq data: ...
Table S1. Number of patients for breast cancer subtype in the TCGA dataset according to IHC status. ...
Figure S2. Frequency and activation state of DC subsets in HLN compared to metastasis negative (SLN-...
Figure S1. Flowcytometric gating of cell subsets. Gating strategies for the DC subsets as well as Tr...
Figure S5. Frequencies and expression of surface molecules of DC subsets in relation to BrC subtype ...
Figure S4. TLR7 and TLR8 expression in LN DC subsets and R848-induced activation in tumor negative B...
Figure S3. Prognostic effect of LNRcDC CD86 expression levels. Kaplan Meier curves of estimated DFS ...
Patient and Tumour Characteristics, Responses to Neoadjuvant Chemotherapy (nâ=â33). (DOCX 56Â kb
Table S5. Differentially expressed genes representing specific immune cell populations across all th...
Figure S2. Phenotypic analyses of breast duct lymphocytes. a CD161, IL-18Rα, and PLZF expression on ...
Figure S1. Representative staining of ILC populations. ILC were gated on lineage negative, CD45+, CD...
Figure S1. Representative immunohistochemistry (IHC) staining images for CD8, CD4, CD20 and CD68. Im...
Figure S1. Isolation and phenotypic analysis of cDC1s from the spleen of FLT3L-expressing B16 tumor-...
Patient characteristics. Table S2. Antibodies and immunostaining protocols. Table S3. Associations b...
Figure S1. Expression of CD19/CD20, CD79A/B and RAG1/RAG2 in blood cancer cell lines. X axis: 164 bl...
quanTIseq signature matrix and used RNA-seq data from purified/enriched immune cells. RNA-seq data: ...
Table S1. Number of patients for breast cancer subtype in the TCGA dataset according to IHC status. ...